CA2705685A1 - Forme dosifiee pharmaceutique contenant un agent antipsychotique - Google Patents

Forme dosifiee pharmaceutique contenant un agent antipsychotique Download PDF

Info

Publication number
CA2705685A1
CA2705685A1 CA2705685A CA2705685A CA2705685A1 CA 2705685 A1 CA2705685 A1 CA 2705685A1 CA 2705685 A CA2705685 A CA 2705685A CA 2705685 A CA2705685 A CA 2705685A CA 2705685 A1 CA2705685 A1 CA 2705685A1
Authority
CA
Canada
Prior art keywords
quetiapine
controlled release
pharmaceutically acceptable
dosage form
eudragit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2705685A
Other languages
English (en)
Inventor
David Wai Fung Ma
Prashant Manohar Mandaogade
Naresh Talwar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmascience Inc
Original Assignee
Pharmascience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmascience Inc filed Critical Pharmascience Inc
Priority to CA2705685A priority Critical patent/CA2705685A1/fr
Priority to CA2800910A priority patent/CA2800910A1/fr
Priority to SG2013005178A priority patent/SG187172A1/en
Priority to PCT/CA2011/000620 priority patent/WO2011147025A1/fr
Priority to EP11785946.2A priority patent/EP2575820A4/fr
Publication of CA2705685A1 publication Critical patent/CA2705685A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2705685A 2010-05-27 2010-05-27 Forme dosifiee pharmaceutique contenant un agent antipsychotique Abandoned CA2705685A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA2705685A CA2705685A1 (fr) 2010-05-27 2010-05-27 Forme dosifiee pharmaceutique contenant un agent antipsychotique
CA2800910A CA2800910A1 (fr) 2010-05-27 2011-05-27 Forme pharmaceutique a liberation prolongee comprenant de la quetiapine
SG2013005178A SG187172A1 (en) 2010-05-27 2011-05-27 Controlled release dosage form comprising quetiapine
PCT/CA2011/000620 WO2011147025A1 (fr) 2010-05-27 2011-05-27 Forme pharmaceutique à libération prolongée comprenant de la quétiapine
EP11785946.2A EP2575820A4 (fr) 2010-05-27 2011-05-27 Forme pharmaceutique à libération prolongée comprenant de la quétiapine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2705685A CA2705685A1 (fr) 2010-05-27 2010-05-27 Forme dosifiee pharmaceutique contenant un agent antipsychotique

Publications (1)

Publication Number Publication Date
CA2705685A1 true CA2705685A1 (fr) 2011-11-27

Family

ID=45003170

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2705685A Abandoned CA2705685A1 (fr) 2010-05-27 2010-05-27 Forme dosifiee pharmaceutique contenant un agent antipsychotique
CA2800910A Abandoned CA2800910A1 (fr) 2010-05-27 2011-05-27 Forme pharmaceutique a liberation prolongee comprenant de la quetiapine

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2800910A Abandoned CA2800910A1 (fr) 2010-05-27 2011-05-27 Forme pharmaceutique a liberation prolongee comprenant de la quetiapine

Country Status (4)

Country Link
EP (1) EP2575820A4 (fr)
CA (2) CA2705685A1 (fr)
SG (1) SG187172A1 (fr)
WO (1) WO2011147025A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014155387A1 (fr) * 2013-03-24 2014-10-02 Tushar Patel Formes galéniques à libération prolongée de sels de quétiapine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050158383A1 (en) * 2003-10-21 2005-07-21 Garth Boehm Quetiapine formulations
US20090035370A1 (en) * 2007-08-02 2009-02-05 Drugtech Corporation Dosage form and method of use
US7794750B2 (en) * 2008-06-20 2010-09-14 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
US8632805B2 (en) * 2008-06-20 2014-01-21 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
EP2153834A3 (fr) * 2008-08-07 2010-02-24 Farmaprojects, S.A. Compositions pharmaceutiques à libération prolongée comportant des sels de quétiapine

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014155387A1 (fr) * 2013-03-24 2014-10-02 Tushar Patel Formes galéniques à libération prolongée de sels de quétiapine

Also Published As

Publication number Publication date
EP2575820A4 (fr) 2014-01-08
EP2575820A1 (fr) 2013-04-10
SG187172A1 (en) 2013-02-28
WO2011147025A1 (fr) 2011-12-01
CA2800910A1 (fr) 2011-12-01

Similar Documents

Publication Publication Date Title
CN1988891B (zh) 包衣片制剂和方法
CA2652712C (fr) Compositions pharmaceutiques stabilisees contenant de la fesoterodine
TWI538700B (zh) 伊伐佈雷定或其可藥用鹽的緩釋製劑
CA2739751C (fr) Compositions pharmaceutiques comprenant de l'hydromorphone et de la naloxone
KR20070050081A (ko) 프라미펙솔 또는 약제학적으로 허용되는 이의 염을포함하는 연장 방출형 펠렛 제형, 이의 제조방법 및 이의용도
EP3313187B1 (fr) Formulation à libération prolongée et comprimés préparés à partir de celle-ci
US20110052648A1 (en) Oral modified-release formulations containing thiazepines
US20110151002A1 (en) Sustained release pharmaceutical compositions comprising quetiapine
WO2011037976A2 (fr) Formulations pharmaceutiques de pramipexole
US20090264408A1 (en) Extended release dosage forms of quetiapine
US20090220593A1 (en) Extended release dosage forms of quetiapine
US20080118554A1 (en) Pharmaceutical compositions comprising a combination of piperidinoalkanol and decongestant
WO2014096982A1 (fr) Compositions pharmaceutiques stables de saxagliptine ou des sels de celle-ci
CN109001353B (zh) 富马酸喹硫平片剂药物组合物和制法
CA2705685A1 (fr) Forme dosifiee pharmaceutique contenant un agent antipsychotique
WO2014096983A1 (fr) Compositions pharmaceutiques stables de saxagliptin ou des sels de celui-ci
KR20210012082A (ko) 미라베그론 및 탐스로신을 포함하는 약학 조성물
KR102727080B1 (ko) 고혈압 및 고콜레스테롤혈증을 치료 또는 예방하기 위한 단일 제형의 약학 조성물
KR20200067406A (ko) 베포타스틴의 방출 제어형 경구 제제
CA3226799A1 (fr) Composition pharmaceutique multiparticulaire
WO2025144120A1 (fr) Formulation pharmaceutique multicouche de mirabégron et de succinate de solifénacine
KR101515222B1 (ko) 티아넵틴 나트륨 함유 제어방출성 경구용 단층 제제 및 이의 제조방법
OA16241A (en) Pharmaceutical compositions comprising hydromorphone and naloxone.
WO2007122474A2 (fr) Formulations à libération prolongée

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20130528